Feature

States judged on smoking cessation services


 

Minnesota and South Carolina are at the top of the class for access to smoking cessation services, but a new report card from the American Lung Association shows that the treatment coverage in most states earned barely passable or failing grades.

In fact, 31 states received either a D (11 states) or an F (20 states) on the grading system. There were also 11 C’s and 7 B’s to go along with the two A’s, the ALA said in “State of Tobacco Control 2018.”

States' access to smoking cessation services graded
The cessation coverage grades are based on a 70-point total, with a maximum of 40 points awarded for a state’s Medicaid coverage (smoking rates are much higher and incomes lower among Medicaid enrollees than the general population), 20 points for the investment per smoker in the state’s phone quitline, and 10 points for state employee health plan coverage.

Minnesota received 66 points and South Carolina earned 63 after a 5-point deduction for not expanding Medicaid up to Affordable Care Act standards. The highest-finishing states with B’s were Vermont with 62 points and Maine with 61, and the lowest total score was the 23 points earned by Virginia and Washington, although Washington’s grade did not include the state employee category since the state did not provide data on its plan, the ALA noted.


The Department of Health & Human Services recommends that tobacco cessation coverage include the use of five nicotine-replacement therapies (gum, patch, lozenge, nasal spray, inhaler), bupropion and varenicline (nonnicotine medications), and three types of counseling (individual, group, and phone), the report said.

“It’s imperative that all state Medicaid programs cover a comprehensive tobacco cessation benefit, with no barriers, to help smokers quit, including all seven [Food and Drug Administration]–approved medications and three forms of counseling for Medicaid enrollees. In 2017, only Kentucky, Missouri, and South Carolina provided this coverage,” wrote Harold P. Wimmer, national president and CEO of the ALA.

Recommended Reading

Clinical presentation, diagnosis, and management of typical and atypical bronchopulmonary carcinoid
MDedge Hematology and Oncology
Expanding treatment options for diverse neuroendocrine tumors
MDedge Hematology and Oncology
Sequential chemotherapy and radiotherapy may be best in locally advanced NSCLC with negative margins
MDedge Hematology and Oncology
Government insurance linked with lower likelihood of radiation therapy for limited-stage small cell lung cancer
MDedge Hematology and Oncology
Phase 1 study: Human IL-10 plus checkpoint blockade looks promising in RCC, NSCLC
MDedge Hematology and Oncology
Young e-cigarette users graduating to the real thing
MDedge Hematology and Oncology
Immune-modified RECIST can help identify survival benefit from cancer immunotherapy
MDedge Hematology and Oncology
New multi-analyte blood test shows promise in screening for several common solid tumors
MDedge Hematology and Oncology
Analysis of Twitter lung cancer content reveals opportunity for clinicians
MDedge Hematology and Oncology
Pembrolizumab plus SBRT shows promise for advanced solid tumors
MDedge Hematology and Oncology